Advertisement
A vs SYK
Which Stock Would AI Choose? Agilent Technologies (A) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Agilent Technologies (A) reported second-quarter fiscal 2026 revenue of $1.83 billion, reflecting 10.0% reported growth and 6.3% core growth year-over-year, alongside double-digit non-GAAP EPS expansion.
- Stryker (SYK) is scheduled to release second-quarter 2026 results on July 30, 2026, following a first-quarter adjusted EPS miss relative to estimates.
- Over recent market activity, A shares have shown relative resilience with modest year-to-date gains, while SYK has experienced a year-to-date decline amid broader medtech sector pressures.
- A operates primarily in life sciences, diagnostics, and applied chemical markets with exposure to analytical instruments, whereas SYK focuses on medical devices and orthopedic solutions with higher capital intensity.
- Recent developments for A include the launch of an AI-driven analysis module, while SYK emphasized dividend stability and organic growth guidance in prior updates.
- Both companies maintain investment-grade balance sheets, though relative momentum in recent weeks has favored A following its earnings release.
Introduction
This comparison examines Agilent Technologies (A) and Stryker (SYK) to highlight differences in business models, recent performance trends, and market positioning. Institutional investors, growth-oriented traders, and sector analysts monitoring healthcare and life sciences often review such pairings when assessing relative value within defensive growth segments. The analysis draws on verifiable financial metrics and developments from recent market activity to provide a factual basis for evaluating these two established companies.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides application-focused solutions in life sciences, diagnostics, and applied chemical markets through segments including Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets. In recent weeks, the stock has demonstrated relative stability following its fiscal second-quarter 2026 earnings release, which showed revenue of $1.83 billion, up 10.0% reported and 6.3% on a core basis. GAAP EPS reached $1.20, supported by margin expansion and double-digit non-GAAP EPS growth. Sentiment received an additional lift from the introduction of an AI-driven analysis module for its xCELLigence RTCA eSight platform. Year-to-date returns have been modestly positive at approximately 1.23%, contrasting with broader market benchmarks, while analyst consensus targets remain elevated around $160.
Stryker (SYK) Overview and Recent Performance
Stryker (SYK) develops and manufactures medical devices and equipment, with core operations in orthopedics, medical and surgical products, and neurotechnology. Recent market activity has reflected a more measured tone, with shares trading lower on a year-to-date basis by roughly 6.8% amid sector rotation and valuation considerations. The company declared its quarterly dividend in early July 2026 and reaffirmed prior full-year organic growth expectations in earlier communications. Attention is now focused on the upcoming second-quarter 2026 earnings release scheduled for July 30, 2026, following a first-quarter adjusted EPS result that fell short of consensus estimates. Market capitalization remains substantial, supported by a diversified product portfolio and recurring revenue streams from implants and consumables.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a broader universe of hundreds available on the platform. These bots trade thousands of different tickers across equities, options, and other instruments, yet only those demonstrating the strongest alignment with prevailing market conditions, consistent risk-adjusted returns, and robust statistical profiles earn placement in the trending section. Available bots span diverse trading styles, timeframes, strategies, and performance metrics, with many exhibiting win rates above 60% and favorable profit factors in backtested and live environments. The section serves as a dynamic resource for traders seeking data-driven signals tailored to current conditions. Explore the full selection at the Trending AI Robots page.
Head-to-Head Comparison
Agilent Technologies (A) and Stryker (SYK) operate in adjacent but distinct healthcare-adjacent sectors, creating clear contrasts in growth drivers and risk profiles. A derives revenue primarily from analytical instruments and services with exposure to research and development spending cycles, while SYK relies on procedure volumes and capital equipment sales within hospitals and ambulatory settings. Recent momentum has tilted toward A following its earnings beat and product innovation announcement, whereas SYK faces near-term scrutiny ahead of its quarterly update. Sector exposure differs notably: A benefits from life sciences and diagnostics tailwinds, while SYK maintains broader orthopedic and surgical device positioning. Risk factors include supply chain dependencies for both, though SYK’s higher fixed-cost structure introduces greater operating leverage sensitivity. Market sentiment in recent weeks has reflected greater stability for A relative to SYK’s more pronounced year-to-date drawdown.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, product innovation catalysts, and relative price stability in the current environment, Tickeron’s AI models would likely assign a probabilistic edge to Agilent Technologies (A) over Stryker (SYK) at this juncture. Trend consistency following the fiscal second-quarter results and the introduction of AI-enhanced offerings provide measurable support for near-term positioning, though outcomes remain contingent on broader macroeconomic conditions and subsequent quarterly disclosures.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and SYK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 2 TA indicator(s) are bullish while SYK’s TA Score has 6 bullish TA indicator(s).
- A’s TA Score: 2 bullish, 5 bearish.
- SYK’s TA Score: 6 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а +2.75% price change this week, while SYK (@Medical/Nursing Services) price change was +0.99% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.81%. For the same industry, the average monthly price growth was +11.88%, and the average quarterly price growth was +7.07%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.20%. For the same industry, the average monthly price growth was -0.54%, and the average quarterly price growth was -16.57%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical Specialties (-0.81% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-1.20% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| A | SYK | A / SYK | |
| Capitalization | 37.9B | 126B | 30% |
| EBITDA | 1.96B | 6.44B | 30% |
| Gain YTD | -0.716 | -5.666 | 13% |
| P/E Ratio | 26.97 | 38.17 | 71% |
| Revenue | 7.23B | 25.3B | 29% |
| Total Cash | 1.81B | N/A | - |
| Total Debt | 3.36B | 14.7B | 23% |
A | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 59 | |
SMR RATING 1..100 | 44 | 57 | |
PRICE GROWTH RATING 1..100 | 49 | 57 | |
P/E GROWTH RATING 1..100 | 63 | 80 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (8) in the Biotechnology industry is in the same range as SYK (10) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (59) in the Medical Specialties industry is somewhat better than the same rating for A (100) in the Biotechnology industry. This means that SYK’s stock grew somewhat faster than A’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is in the same range as SYK (57) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
A's Price Growth Rating (49) in the Biotechnology industry is in the same range as SYK (57) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
A's P/E Growth Rating (63) in the Biotechnology industry is in the same range as SYK (80) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
| A | SYK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 65% | 3 days ago 54% |
| Stochastic ODDS (%) | 3 days ago 64% | 3 days ago 51% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 55% |
| MACD ODDS (%) | 3 days ago 68% | 4 days ago 49% |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 47% |
| Advances ODDS (%) | 3 days ago 60% | 3 days ago 56% |
| Declines ODDS (%) | 7 days ago 63% | 12 days ago 53% |
| BollingerBands ODDS (%) | 3 days ago 64% | 3 days ago 47% |
| Aroon ODDS (%) | N/A | 3 days ago 45% |
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.